intravenous fosfomycin

This presentation explores intravenous fosfomycin, focusing on its use in the ZEUS trial, which compared ZTI-01 to PIP-TAZ for treating infections. Key findings include its efficacy, safety, and microbiological outcomes, alongside the unique mechanism of action against multidrug-resistant bacteria. Clinical implications highlight its role in managing complicated urinary tract infections and its advantages over existing treatments in addressing antibiotic resistance. Challenges such as adverse...